Treatment with tandem [90Y]DOTA-TATE an [177Lu]DOTA- TATE of neuroendocrine tumors refractory to conventional therapy: Preliminary results

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 1, 2010, Pages 84-91

  Seregni, E ^a   Maccauro, M ^a   Coliva, A ^a   Castellani, M R ^a   Bajetta, E ^a   Aliberti, G ^a   Vellani, C ^b   Chiesa, C ^a   Martinetti, A ^a   Bogni, A ^a   Bombardieri, E ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Neuroendocrine tumors; Radiotherapy; Receptors; Somatostatin

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTATE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTATE Y 90; RADIOISOTOPE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD SAMPLING; BRONCHIAL NEUROENDOCRINE TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSIMETRY; FEASIBILITY STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN TISSUE; INTESTINAL NEUROENDOCRINE TUMOR; LEUKOPENIA; MALE; MEDIASTINAL NEUROENDOCRINE TUMOR; MULTIPLE CYCLE TREATMENT; NASAL NEUROENDOCRINE TUMOR; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; ORGAN; PANCREAS NEUROENDOCRINE TUMOR; PARAGANGLIOMA; PROTEIN EXPRESSION; RETRORECTAL NEUROENDOCRINE TUMOR; SCINTIGRAPHY; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIOMETRY; TREATMENT OUTCOME;

EID: 77952474920     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Current Opinions in Oncology 2000;12:368-377
2. Krenning EP, Teunissen JJ, Valkema R, deHerder WW, dejong M, Kwekkeboom DJ. Molecular radiotherapy widi somatostatin analogs for (neuroOendocrine tumors. Endocrinol Invest 2005;28(11 Suppl):146-150
3. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Reviews 2003;24:389-427. (Pubitemid 37056239)
4. Janson ET, Westlin J, Ohrvall U, Oberg K, Lukinius A. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1] octreotide in patients with neuroendocrine tumors. J Nucl Med 2000;41:1514-1518
5. De Jong M, Bernard BF, De Bruin E, Van Gameren A, Bakker WH, Visser TJ etal. Internalization of radiolabelled [DTPAO] octreotide and [DOTAO, Tyr3] octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 1998;19:283-288
6. Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 2002;57: 749-763 (Pubitemid 35279166)
7. Volkert WA, Hoffman TJ. Thrapeutic radiopharmaceuticals. Chem Rev 1999;99:2269-2292
8. Krenning EP, Valkema R, Kooij PP, Breeman WA, Bakker WH, deHerder WW et al. Scintigraphy and radionuclide therapy with [indium-111-labelled- diethyltriamine penta-acetic acid-D-Phe1]octreotide. Ital J Gastroenterol Hepatol 1999;31(Suppl 2): S219-S23.
9. 90Y-DOTA-TOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30:207-216
10. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (9O)Y-DOTATOC. J Nucl Med 2002;43:610-616
11. 177Lu- DOTAO,Tyr3)Octreotate: Toxicity, Efficacy, and Survival. J Clin Oncol 2008;26:2124-2130
12. 177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAO]octreotide in patients. Eur J Nucl Med 2001;28:1319-1325
13. 111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991 ;49: 1583-1591
14. 90Y-ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2009;36:1745-1757
15. Glatting G, Landmann M, Kull T, Wunderlich A, Blumstein NM, Buck AK et al. Internal radionuclide therapy: The ULMDOS software for treatment planning. Med Phys 2005;32: 2399-2405 (Pubitemid 41023200)
16. 90Y-ibritumomab tiuxetan. Cancer Biother Radiopharm 2008;23:633-639
17. 90YDOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose-Effect Relationship. J Nucl Med 2005;46:99S-106S.
18. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol 1996;41:1871-1885
19. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G.. Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47:1467-1475 (Pubitemid 47544933)
20. 90Y-labeled somatostatin analogs. J Nucl Med 2O05;46:13S-7S.